Holen Sie sich die Stockscreener-App
30.50
8.74%
-2.92
Handel nachbörslich:
30.01
-0.49
-1.61%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel (NASDAQ:CAPR) - Seeking Alpha
Capricor Therapeutics (CAPR) Shares Recommended for Purchase Ami - GuruFocus
Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss - marketscreener.com
CAPR Stock: Analyst B. Riley Securities Raises Price Target to $63 | CAPR Stock News - GuruFocus
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates - Benzinga
CAPR: Piper Sandler Raises Price Target to $58, Reiterates Overw - GuruFocus
Trading the Move, Not the Narrative: (CAPR) Edition - Stock Traders Daily
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone - MSN
Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial Challenges - GuruFocus
Capricor Therapeutics (CAPR) Advances Duchenne Therapy with FDA Review - GuruFocus
Capricor Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Capricor (CAPR) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts - Investing.com Nigeria
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Capricor Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts By Investing.com - Investing.com UK
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Capricor Looks Ahead To Deramiocel Approval In DMD - Citeline News & Insights
Capricor Therapeutics falls on Q4 earnings miss By Investing.com - Investing.com Canada
Capricor (CAPR) Focuses on Deramiocel's Approval Amid Financial Growth - GuruFocus
Capricor’s DMD therapy shows heart benefit in phase 3 trial | Tap to know more | Inshorts - Inshorts
Capricor: Q4 Earnings Snapshot - marketscreener.com
Earnings Flash (CAPR) Capricor Therapeutics Posts Q4 Loss $-0.62, vs. FactSet Est of Loss of $-0.55 - marketscreener.com
Fourth quarter and full year 2025 earnings released, Capricor Therapeutics, Inc. outlines - Traders Union
Duchenne trial drug from Capricor slows key task decline 83% - Stock Titan
Capricor Therapeutics’ DMD treatment study shows improvement in key heart function measures - MSN
Is It Too Late To Consider Capricor Therapeutics (CAPR) After Strong Multi Year Share Gains? - simplywall.st
Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy - Stocktwits
Capricor Therapeutics’ DMD Treatment Study Shows Improvement In Key Heart Function Measures - Asianet Newsable
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor Therapeutics (CAPR) Reveals Promising Data from Phase 3 HOPE-3 Trial - GuruFocus
Capricor earnings on deck after FDA resumes deramiocel review By Investing.com - Investing.com Nigeria
CAPR Stock In Focus: Capricor Says Phase 3 DMD Trial Shows Cardiac Improvement With Deramiocel - Stocktwits
Capricor earnings on deck after FDA resumes deramiocel review - Investing.com UK
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy - The Manila Times
Cell therapy for Duchenne slows key eating task decline by 83% - Stock Titan
Capricor: Fourth Quarter Financial Results Overview - Bitget
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Capricor Therapeutics (CAPR) Set to Announce Q4 Earnings - GuruFocus
Capricor Therapeutics Hits Day High with Strong 9.04% Intraday Surge - Markets Mojo
FDA resumes review of Capricor’s cell therapy deramiocel - The Pharma Letter
Capricor Therapeutics Hits Day High with Strong 9.78% Intraday Surge - Markets Mojo
FDA resumes review of Capricor’s Deramiocel for DMD treatment By Investing.com - Investing.com Canada
Why Capricor Therapeutics (CAPR) Is Up 29.3% After FDA Resumes Review of Deramiocel BLA - Sahm
Capricor Therapeutics (CAPR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
H.C. Wainwright Maintains Buy on Capricor Therapeutics, Inc. (CAPR) Mar 2026 - Meyka
Capricor Therapeutics (CAPR) Surges as FDA Reviews Key Therapy - GuruFocus
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Sahm
Capricor Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Capricor Therapeutics Rises as FDA Lifts Complete Response Letter, Resumes Review - marketscreener.com
Capricor Therapeutics Sees Surge in Trading Volume - National Today
Capricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Jones Trading reiterates Capricor stock Buy on FDA review resumption By Investing.com - Investing.com Canada
Capricor extends rally as FDA to review rejected cell therapy - MSN
HC Wainwright Reiterates Buy Rating for Capricor Therapeutics (C - GuruFocus
Capricor Advances Deramiocel BLA Review for Duchenne DMD - TipRanks
Capricor Therapeutics stock surges on FDA BLA review resumption - Investing.com
Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright - MarketBeat
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Capricor resumes FDA BLA review for Deramiocel; PDUFA date set for Aug 22, 2026 - TradingView
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):